

# SENATE BILL NO. 616

October 22, 2025, Introduced by Senator SANTANA and referred to Committee on Civil Rights, Judiciary, and Public Safety.

A bill to amend 2022 PA 85, entitled  
"Opioid liability litigation act,"  
by amending sections 2 and 3 (MCL 691.1672 and 691.1673), as  
amended by 2023 PA 228.

**THE PEOPLE OF THE STATE OF MICHIGAN ENACT:**

1       Sec. 2. As used in this act:  
2       (a) "Allergan settlement" means the master settlement  
3       agreement arising out of the MDL and entered into by this state  
4       with Allergan Pharmaceuticals.

1           (b) "Alvogen settlement" means the master settlement agreement  
2 arising out of the MDL and entered into by this state with Alvogen,  
3 Incorporated.

4           (c) "Amneal settlement" means the master settlement agreement  
5 arising out of the MDL and entered into by this state with Amneal  
6 Pharmaceuticals, LLC.

7           (d) "Apotex settlement" means the master settlement agreement  
8 arising out of the MDL and entered into by this state with Apotex  
9 Corporation.

10          (e) ~~(b)~~ "CVS settlement" means the master settlement agreement  
11 arising out of the MDL and entered into by this state with CVS  
12 Pharmacy.

13          (f) ~~(e)~~ "Distributor settlement" means the master settlement  
14 agreement arising out of the MDL and entered into by this state  
15 with AmerisourceBergen Corporation, Cardinal Health, Inc., and  
16 McKesson Corporation.

17          (g) "Hikma settlement" means the master settlement agreement  
18 arising out of the MDL and entered into by this state with Hikma  
19 Pharmaceuticals USA, Incorporated.

20          (h) "Indivior settlement" means the master settlement  
21 agreement arising out of the MDL and entered into by this state  
22 with Indivior, Incorporated.

23          (i) ~~(d)~~ "Janssen settlement" means the master settlement  
24 agreement arising out of the MDL and entered into by this state  
25 with Janssen Pharmaceuticals, Inc.

26          (j) "Kroger settlement" means the master settlement agreement  
27 arising out of the MDL and entered into by this state with the  
28 Kroger Co.

29          (k) ~~(e)~~ "MDL" means *In re Nat'l Prescription Opiate*

1 *Litigation*, multidistrict litigation consolidated in the United  
2 States District Court for the Northern District of Ohio, Case No.  
3 1:17-MD-2804.

4 **(l) "Mylan settlement" means the master settlement agreement**  
5 **arising out of the MDL and entered into by this state with Viatris,**  
6 **Inc.**

7 **(m) ~~(f)~~**—"Political subdivision" means a public body corporate  
8 in this state, an agency of a public body corporate in this state,  
9 a nonincorporated body in this state of whatever nature, or an  
10 agency of a nonincorporated body in this state. Political  
11 subdivision includes a county, city, village, township, school  
12 district, or special district or authority of this state. Political  
13 subdivision does not include this state.

14 **(n) "Purdue settlement" means the Governmental Entity and**  
15 **Shareholder Direct Settlement Agreement in the bankruptcy action *In***  
16 ***re Purdue Pharma LP et al*, Case No. 19-23649 (SHL) (Bankr SDNY), to**  
17 **which this state is a party.**

18 **(o) "Sun settlement" means the master settlement agreement**  
19 **arising out of the MDL and entered into by this state with Sun**  
20 **Pharmaceuticals, Incorporated.**

21 **(p) ~~(g)~~**—"Teva settlement" means the master settlement  
22 agreement arising out of the MDL and entered into by this state  
23 with Teva Pharmaceuticals.

24 **(q) ~~(h)~~**—"Walgreens national settlement" means the master  
25 settlement agreement arising out of the MDL and entered into by  
26 this state with Walgreens Pharmacy.

27 **(r) ~~(i)~~**—"Walmart settlement" means the master settlement  
28 agreement arising out of the MDL and entered into by this state  
29 with Walmart.

1       **(s) "Zydus settlement" means the master settlement agreement**  
2 **arising out of the MDL and entered into by this state with Zydus**  
3 **Pharmaceuticals (USA), Inc.**

4       Sec. 3. A political subdivision of this state shall not  
5 commence or maintain an action as follows:

6       (a) After January 1, 2021, an action related to the released  
7 claims as defined in the distributor settlement against the  
8 released entities as defined in the distributor settlement.

9       (b) After January 1, 2021, an action related to the released  
10 claims as defined in the Janssen settlement against the released  
11 entities as defined in the Janssen settlement.

12       (c) After January 1, 2022, an action related to the released  
13 claims as defined in the Allergan settlement against the released  
14 entities as defined in the Allergan settlement.

15       (d) After January 1, 2022, an action related to the released  
16 claims as defined in the CVS settlement against the released  
17 entities as defined in the CVS settlement.

18       (e) After January 1, 2022, an action related to the released  
19 claims as defined in the Teva settlement against the released  
20 entities as defined in the Teva settlement.

21       (f) After January 1, 2022, an action related to the released  
22 claims as defined in the Walgreens national settlement against the  
23 released entities as defined in the Walgreens national settlement.

24       (g) After January 1, 2022, an action related to the released  
25 claims as defined in the Walmart settlement against the released  
26 entities as defined in the Walmart settlement.

27       **(h) After January 1, 2024, an action related to the released**  
28 **claims as defined in the Kroger settlement against the released**  
29 **entities as defined in the Kroger settlement.**

1 (i) After January 1, 2025, an action related to the  
2 Shareholder Released Claims as defined in the Purdue settlement  
3 against the Shareholder Released Persons as defined in the Purdue  
4 settlement.

5 (j) After January 1, 2025, an action related to the released  
6 claims as defined in the Alvogen settlement against the released  
7 entities as defined in the Alvogen settlement.

8 (k) After January 1, 2025, an action related to the released  
9 claims as defined in the Amneal settlement against the released  
10 entities as defined in the Amneal settlement.

11 (l) After January 1, 2025, an action related to the released  
12 claims as defined in the Apotex settlement against the released  
13 entities as defined in the Apotex settlement.

14 (m) After January 1, 2025, an action related to the released  
15 claims as defined in the Hikma settlement against the released  
16 entities as defined in the Hikma settlement.

17 (n) After January 1, 2025, an action related to the released  
18 claims as defined in the Indivior settlement against the released  
19 entities as defined in the Indivior settlement.

20 (o) After January 1, 2025, an action related to the released  
21 claims as defined in the Mylan settlement against the released  
22 entities as defined in the Mylan settlement.

23 (p) After January 1, 2025, an action related to the released  
24 claims as defined in the Sun settlement against the released  
25 entities as defined in the Sun settlement.

26 (q) After January 1, 2025, an action related to the released  
27 claims as defined in the Zydus settlement against the released  
28 entities as defined in the Zydus settlement.